|Bid||3.25 x 500|
|Ask||3.28 x 800|
|Day's Range||3.24 - 3.45|
|52 Week Range||2.66 - 8.40|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
OPKO Health (OPK) posts lackluster Q4 numbers due to rising operating expenses owing to investments associated with the launch of RAYALDEE and consistent investments in the pharmaceutical pipeline.
Both revenues and profits of the biotechnology firm founded by South Florida business magnate Dr. Phillip Frost declined in the fourth quarter of 2017, sending its stock plummeting 15 percent following release of quarterly results. In January, the president of BioReference, Gregory Henderson, resigned.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! J C Penney Company Inc (NYSE: JCP ) stock lost more ...
The Miami-based company said it had a loss of 38 cents per share. Losses, adjusted for pretax expenses and asset impairment costs, came to 25 cents per share. The results fell short of Wall Street expectations. ...
Opko Health (NYSE: OPK ) unveils its next round of earnings Thursday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement Earnings and Revenue Based on Opko Health management ...
Insider buying can be an encouraging signal for potential investors. Several health care companies saw notable insider buying this past week. Insiders included a company founder and a renowned former CEO. ...
Insider buying can be an encouraging signal for potential investors. Insiders at three companies made notable share purchases last week. And two of the insiders featured here are regular acquirers of shares. ...
The president of Opko Health's diagnostics division, which accounts for a large share of the company's revenue, has resigned. Opko, majority owned by Miami billionaire investor Phillip Frost, announced Wednesday that Gregory Henderson has left BioReference Laboratories, the third largest commercial testing lab in the U.S. for physician offices, clinics, hospitals, employers and governmental units. Opko (OPK) acquired the New Jersey-based diagnostics company in August 2015 for $1.5 billion in an all-stock deal.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to OPKO Health, Inc. Here are 5 ETFs with the largest exposure to OPK-US. Comparing the performance and risk of OPKO Health, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis OPKO Health, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of OPKO Health, Inc. – TESARO, Inc., Johnson & Johnson, Abbott Laboratories, Regeneron Pharmaceuticals, Inc., Ardelyx, Inc., Bristol-Myers Squibb Company, Laboratory Corporation of America Holdings, Novelion Therapeutics Inc., Alnylam ... Read more (Read more...)
OPKO Health (OPK) posts lackluster Q3 numbers due to rising operating expenses owing to investment associated to the launch of RAYALDEE, and consistent investment in the pharmaceutical pipeline.
Opko Health Inc. (NASDAQ:OPK) delivered a sore sight to the Street yesterday with a sharp third quarter miss in earnings that has sent investors scrambling away in the aftermath. However, Cantor analyst Louise Chen makes a confident case for the drug maker's "underappreciated" earnings potential.
Opko Health Inc. (NASDAQ:OPK) reports operating and financial results for the three months ended September 30, 2017.